LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Home・Akciju saraksts・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

7.62 -0.13

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.55

Max

7.62

Galvenie mērījumi
By Trading Economics
Ienākumi	5.1M 5.1M
Pārdošana	18M 163M
Peļņas marža	3.113
Darbinieki	580
EBITDA	7.2M 28M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+129.36% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 3. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-172M 1.7B
Iepriekšējā atvēršanas cena	7.75
Iepriekšējā slēgšanas cena	7.62

Ziņu noskaņojums

By Acuity

50%

132 / 371 Rangs Healthcare

BioCryst Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 26. sept. 18:25 UTC

Galvenie tirgus virzītāji

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

2025. g. 27. sept. 07:00 UTC

Peļņas

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

2025. g. 27. sept. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 26. sept. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

2025. g. 26. sept. 20:54 UTC

Peļņas

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

2025. g. 26. sept. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 26. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 26. sept. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025. g. 26. sept. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 26. sept. 19:54 UTC

Tirgus saruna

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

2025. g. 26. sept. 19:53 UTC

Iegādes, apvienošanās, pārņemšana

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025. g. 26. sept. 19:40 UTC

Peļņas

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

2025. g. 26. sept. 19:24 UTC

Tirgus saruna

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

2025. g. 26. sept. 19:17 UTC

Tirgus saruna

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

2025. g. 26. sept. 19:15 UTC

Tirgus saruna

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

2025. g. 26. sept. 19:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. sept. 19:03 UTC

Tirgus saruna

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

2025. g. 26. sept. 18:50 UTC

Tirgus saruna

Peļņas

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

2025. g. 26. sept. 18:36 UTC

Tirgus saruna

Silver Closes Out Week With Strong Surge -- Market Talk

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: Global Development Hasn't Received All Necessary Approvals >ING

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

2025. g. 26. sept. 17:54 UTC

Tirgus saruna

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

2025. g. 26. sept. 16:56 UTC

Tirgus saruna

Peļņas

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

2025. g. 26. sept. 16:41 UTC

Tirgus saruna

Peļņas

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

2025. g. 26. sept. 16:26 UTC

Peļņas

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

2025. g. 26. sept. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 26. sept. 16:12 UTC

Tirgus saruna

Nike Stock Seen With Limited Upside -- Market Talk

2025. g. 26. sept. 15:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. sept. 15:59 UTC

Tirgus saruna

Nike Seen Showing Progress in Turnaround -- Market Talk

Salīdzinājums

Cenas izmaiņa

BioCryst Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

129.36% augšup

Prognoze 12 mēnešiem

Vidējais 17.5 USD 129.36%

Augstākais 30 USD

Zemākais 12 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi BioCryst Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam BioCryst Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

132 / 371 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.